Resources
View resources about cytomegalovirus and CYTOGAM® (Cytomegalovirus Immune Globulin Intravenous [Human]) (CMV-IGIV) as well as the locations of our upcoming engagements.
Learn More About CYTOGAM With Resources for Your Practice, Institution, and Patients
Easily access printable resources and videos to help train staff on the importance of CMV prevention and educate your patients.
Downloadable and Viewable Materials
CYTOGAM Mechanism of Action Video
This animated video represents components of the mechanism of action of CYTOGAM as “characters” to dynamically illustrate the simultaneous steps that occur.1-3
Video Series: Cutting-Edge Strategies Against CMV: Breakthroughs in Hyperimmune Therapy
Science and Innovation Theater
Video 1: Kamada Inc., Hyperimmune Globulins, and the US Clinical Program Overview
Presented by Winston Ally, PharmD
Director, US Medical Affairs, Kamada Inc.
Time: 4:09 minutes
Video 2: Anti-CMV Strategies and Immune Response in Lung Transplantation
Presented by Lorenzo Zaffiri, MD, PhD
Associate Medical Director, Lung Transplant Program, Department of Medicine, Cedars-Sinai
Assistant Professor, Department of Medicine
Time: 14:25 minutes
Emerging Clinical Data: “Lung transplant recipients with high-risk CMV mismatch managed using a multimodality regimen over a 5-year period”
This poster by UTSW presents findings on a retrospective study of lung-transplant patients receiving CYTOGAM combination prophylaxis with an antiviral.4 A full publication is expected in early 2025.
CYTOGAM Brochure
This 2-page brochure contains an overview of CYTOGAM with an emphasis on how its complementary MOA in conjunction with an antiviral combine to provide CMV prophylaxis.1,2
Upcoming Events
CYTOGAM offers webinars to healthcare providers and their staff periodically. Additionally, Kamada Inc. participates annually in medical conferences in the United States and internationally. Events will be posted below as they become available.
Follow for updates and to join Kamada at the 2024/2025 meetings. Kamada is pleased to share information and insights into therapies that help protect solid organ transplant patients and other immunocompromised, high-risk populations. See you there!
References: 1. Grossi PA, Mohacsi P, Szabolcs Z, Potena L. Cytomegalovirus immunoglobulin after thoracic transplantation: an overview. Transplantation. 2016;100:S1-S4. 2. Carbone J. The immunology of posttransplant CMV infection: potential effect of CMV immunoglobulins on distinct components of the immune response to CMV. Transplantation. 2016;100: S11-S18. 3. Deml L, Huber CM, Barabas S, Spindler T, Cozzi E, Grossi P. Stimulatory effect of CMV immunoglobulin on innate immunity and on the immunogenicity of CMV antigens. Transplant Direct. 2021;7:e781. doi:10.1097/TXD.0000000000001236 4. Banga A, Kanade R, Bollineni S, et al. Lung transplant recipients with high-risk CMV mismatch managed using a multimodality regimen over a five-year period. Poster presented at: IDWeek; October 11-15, 2023; Boston, MA.